US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Chronic kidney disease (CKD) is a growing global health concern, significantly contributing to morbidity and mortality rates worldwide. Characterized by a ...
GPs struggle to integrate albuminuria screening for chronic kidney disease due to confusion over prescribing and interpreting ...
The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback